Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
90Y-epratuzumab tetraxetan
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
90Y-epratuzumab tetraxetan is a radioimmunotherapeutic agent composed of the humanized monoclonal antibody epratuzumab, which targets the CD22 antigen on B lymphocytes, conjugated to the radioactive isotope yttrium-90 via a chelator (tetraxetan/DOTA). The drug delivers targeted beta radiation to CD22-expressing tumor cells, resulting in cytotoxicity primarily through DNA damage. It was developed for use in B-cell malignancies such as non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL), with clinical studies showing durable responses especially when administered in repeated low doses or combined with other therapies like rituximab or veltuzumab. Despite promising early results, further development was discontinued due to loss of industrial support and it has not received regulatory approval[1][3][5][6][7][9].
- Other names
- Yttrium (90Y) epratuzumab tetraxetan90Y-DOTA-epratuzumab
02
Targets
CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on 90Y-epratuzumab tetraxetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 90Y-epratuzumab tetraxetan.